These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 15636503)

  • 61. FDA in earnest.
    Nature; 1969 Jan; 221(5177):213. PubMed ID: 5818229
    [No Abstract]   [Full Text] [Related]  

  • 62. FDA to steer nanotech.
    Fox JL
    Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
    [No Abstract]   [Full Text] [Related]  

  • 63. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 64. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health.
    Javitt GH; Stanley E; Hudson K
    Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034
    [No Abstract]   [Full Text] [Related]  

  • 65. Food and Drug Administration inspection and licensing of manufacturing facilities.
    Avallone HL; Beatrice MG; Sze TT
    Bioprocess Technol; 1991; 13():315-40. PubMed ID: 1367137
    [No Abstract]   [Full Text] [Related]  

  • 66. Drug approval. Investigational access stumbles.
    Jenks S
    Med World News; 1988 Mar; 29(6):48-9. PubMed ID: 10302307
    [No Abstract]   [Full Text] [Related]  

  • 67. Effects of scheduling on the economics of drug development.
    Cavallito CJ
    NIDA Res Monogr; 1979; 27():17-28. PubMed ID: 121332
    [No Abstract]   [Full Text] [Related]  

  • 68. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 69. U.S. Food and Drug Administration requests for input on HR 3204 enactment: the Drug Quality and Security Act of 2013.
    Miller DG
    Int J Pharm Compd; 2014; 18(1):35-6. PubMed ID: 24881338
    [No Abstract]   [Full Text] [Related]  

  • 70. A world of hurt.
    Simons J
    Fortune; 2005 Jan; 151(1):17-8, 20. PubMed ID: 15696651
    [No Abstract]   [Full Text] [Related]  

  • 71. Instrument of impediment. The regulatory monograph in medical communications.
    Archer J
    J Kans Med Soc; 1972 Aug; 73(8):385-8. PubMed ID: 5068010
    [No Abstract]   [Full Text] [Related]  

  • 72. Physician liability and drug recalls.
    Johnson LJ
    Med Econ; 2001 Sep; 78(17):118. PubMed ID: 11573390
    [No Abstract]   [Full Text] [Related]  

  • 73. Investigational new drug regs: icing or cake?
    Margolis RE
    Healthspan; 1988 Dec; 5(11):25-6. PubMed ID: 10291398
    [No Abstract]   [Full Text] [Related]  

  • 74. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 75. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of regulations on the development of psychoactive drugs.
    Lasagna L
    NIDA Res Monogr; 1979; 27():29-35. PubMed ID: 121345
    [No Abstract]   [Full Text] [Related]  

  • 77. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
    Daemmrich A
    Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
    [No Abstract]   [Full Text] [Related]  

  • 78. Pain meds in the spotlight. Senate staffers get demo of DEA regulations.
    Connole P
    Provider; 2010 Feb; 36(2):20-1. PubMed ID: 20183969
    [No Abstract]   [Full Text] [Related]  

  • 79. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 80. Patterns of change. Federal Drug Agency responsible for both safety and effectiveness.
    Goddard JL
    R I Med J; 1968 Jul; 51(7):448-52. PubMed ID: 5243980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.